Search results
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Investor's Business Daily· 3 days agoThe cancer vaccine reduced the likelihood cancer would return or patients would die by 49% after...
There might be stockpiles, but making an effective bird flu vaccine won’t be quick or easy
The Telegraph via Yahoo News· 3 days agoHealth officials have been steadfast in their assurances. The risk of H5N1 bird flu jumping into...
Genetics Played a Role in Blood Clots Linked to COVID-19 Shots
Time Magazine· 1 day agoAdenovirus-based vaccines, like the J&J and AstraZeneca shots that were later pulled from the...
Is Novavax Stock A Buy After Nearly Tripling On $1.3 Billion Sanofi Deal?
Investor's Business Daily· 3 days agoShares now have a top Relative Strength Rating of 99. The RS Rating pits all stocks, regardless of...
Expert reaction: AstraZeneca withdraws its COVID-19 vaccine
Cosmos· 6 days agoAstraZeneca developed the first vaccine for COVID-19, beating the competition, but this week they’ve...
Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker
CNBC· 4 days agoA vial labelled "Novavax V COVID-19 Vaccine" is seen in this illustration taken January 16, 2022....
Political Watch: December 2, 2021
Santa Maria Sun· 1 day agoBatjer has served as president for the commission since 2019 and previously served as the first ever secretary of the California Government Operations Agency. “As my lead energy...
"FLiRT" COVID variants are now more than a third of U.S. cases. Scientists share what we know about...
CBS News· 7 days agoMore than a third of COVID-19 cases in the U.S. are now estimated to be from a new, fast-growing...
Will your last COVID vaccine work against new ‘FLiRT’ variants?
The Hill· 5 days agoBoth are sublineages of the JN.1 lineage of the Omicron variant, the main COVID variant for roughly...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 3 days agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...